BriaCell Therapeutics Corp. (BCTX) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
BCTX Revenue Growth
BCTX Revenue Analysis (2014–2025)
As of May 8, 2026, BriaCell Therapeutics Corp. (BCTX) generated trailing twelve-month (TTM) revenue of $0. The most recent quarter (Q2 2026) recorded $0 in revenue.
Looking at the longer-term picture, BCTX's historical revenue data shows various trends over time.
When compared to Healthcare sector peers including NKTR (-43.9% YoY), ADCT (+4.4% YoY), and CRIS (-13.4% YoY). Compare BCTX vs NKTR →
BCTX Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| BCTXCurrent | $0 | - | - | - | |
 NKTR | $55M | -43.9% | -18.4% | -236.8% | |
 ADCT | $81M | +4.4% | - | -133.2% | |
 CRIS | $9M | -13.4% | -2.7% | -348.4% | |
 HALO | $1.4B | +37.6% | +39.2% | 58.4% |
BCTX Historical Revenue Data (2014–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $0 | - | $-147,893 | - | $-37,733,686 | - |
| 2024 | $0 | - | $-114,643 | - | $-45,544,884 | - |
| 2023 | $0 | - | $-20,508 | - | $-31,256,369 | - |
| 2022 | $0 | - | $-19,417 | - | $-19,440,476 | - |
| 2021 | $0 | - | $-19,462 | - | $-8,899,927 | - |
| 2020 | $0 | - | $-18,735 | - | $-4,838,251 | - |
| 2019 | $0 | - | $-18,833 | - | $-6,252,448 | - |
| 2018 | $0 | - | $-16,877 | - | $-4,971,902 | - |
| 2017 | $0 | - | $-289 | - | $-3,214,962 | - |
| 2016 | $0 | - | $-1,803 | - | $-2,193,807 | - |
See BCTX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs BCTX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare BCTX vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonBCTX — Frequently Asked Questions
Quick answers to the most common questions about buying BCTX stock.
Is BCTX's revenue growth accelerating or slowing?
BCTX TTM revenue: $0.00. YoY growth: N/A. 5-year CAGR: N/A.
What is BCTX's long-term revenue growth rate?
BriaCell Therapeutics Corp.'s 5-year revenue CAGR of N/A reflects the variable expansion pattern. Current YoY growth of N/A is near this long-term average.
How is BCTX's revenue distributed by segment?
BCTX reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.